Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: Humabody VH antibody fragment-based therapeutics - Crescendo Biologics

Next Previous
Drug Profile

Research programme: Humabody VH antibody fragment-based therapeutics - Crescendo Biologics

Alternative Names: CB 108; CB 201 - Crescendo Biologics; T-cell enhancer

Latest Information Update: 13 Sep 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Crescendo Biologics
  • Class Antineoplastics; Immunoglobulin fragments; Immunotherapies; Recombinant fusion proteins
  • Mechanism of Action Immunomodulators; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 04 Sep 2023 Crescendo Biologics has patent protection for Methods for producing optimised therapeutic molecules from transgenic animals in Europe
  • 28 May 2022 No recent reports of development identified for preclinical development in Cancer in United Kingdom (Parenteral)
  • 05 May 2020 Crescendo Biologics and Cancer Research UK enters into Clinical Development Partnerships agreement for CB 213 and Crescendo Biologics retains the right to advance the CB 213 program further

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top